Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: An analysis of Radiation Therapy Oncology Group Protocol 92

Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: An analysis of Radiation Therapy Oncology Group Protocol 92–02

Published:2006-11 Issue:4 Volume:66 Page:1064-1071
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Valicenti Richard K.,DeSilvio Michelle,Hanks Gerald E.,Porter Arthur,Brereton Harmar,Rosenthal Seth A.,Shipley William U.,Sandler Howard M.

Publisher

Elsevier BV

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology,Radiation

Reference17 articles.

1. Cancer statistics;Jemal;CA Cancer J Clin,2006

2. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy;D’Amico;J Natl Cancer Inst,2003

3. Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy;Sandler;Int J Radiat Oncol Biol Phys,2000

4. Natural history of progression after PSA elevation following radical prostatectomy;Pound;JAMA,1999

5. Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation;Albertsen;J Urol,2001

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601;Journal of Clinical Oncology;2022-09-20

2. Surrogate Endpoints in Localized Prostate Cancer;The Cancer Journal;2020-01

3. Radiation dose-response (a Bayesian model) in the radiotherapy of the localized prostatic adenocarcinoma: the reliability of PSA slope changes as a response surrogate endpoint;PeerJ;2019-07-01

4. Time Interval to Biochemical Failure as a Surrogate End Point in Locally Advanced Prostate Cancer: Analysis of Randomized Trial NRG/RTOG 9202;Journal of Clinical Oncology;2019-01-20

5. Intermediate Endpoints After Postprostatectomy Radiotherapy: 5-Year Distant Metastasis to Predict Overall Survival;European Urology;2018-10